Abstract A38: Therapeutic targeting of oncogenic KRAS signaling using a novel small molecule agonist of the PP2A tumor suppressor gene
Jaya Sangodkar(Pediatrics and Genetics), Goutham Narla(Pediatrics and Genetics), Yiannis A. Ioannou(Icahn School of Medicine at Mount Sinai), Neelesh Sharma(Bayer (United States)), Danica Wiredja(Case Western Reserve University), Giridharan Gokulrangan(University of Kansas), David B. Kastrinsky(Icahn School of Medicine at Mount Sinai), Daniela Schlatzer(Case Western Reserve University), Analisa DiFeo(University of Michigan), Sahar Mazhar(University of Michigan), Michael Ohlmeyer(Princeton Satellite Systems (United States)), Shen Yao, Sudeh Izadmehr(Icahn School of Medicine at Mount Sinai)
Cited by 0
Related Papers
Functional variants in the <i>LRRK2</i> gene confer shared effects on risk for Crohn’s disease and Parkinson’s disease
|Science Translational Medicine|2018|410
Hepatic Niemann-Pick C1–like 1 regulates biliary cholesterol concentration and is a target of ezetimibe
|Journal of Clinical Investigation|2007|372
Transmembrane Molecular Pump Activity of Niemann-Pick C1 Protein
|Science|2000|324
Topological Analysis of Niemann-Pick C1 Protein Reveals That the Membrane Orientation of the Putative Sterol-sensing Domain Is Identical to Those of 3-Hydroxy-3-methylglutaryl-CoA Reductase and Sterol Regulatory Element Binding Protein Cleavage-activating Protein
|Journal of Biological Chemistry|2000|301